研究業績（原著論文のみ）/ Publications(Original Articles only)

• 2022-2023
• 2020-2021
• 2018-2019

• 2016-2017
• 2015-2014
• 2013-2012
• 2011-2006

2019年度

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K. Sci Rep . 2019 Dec 20;9(1):19501. doi: 10.1038/s41598-019-55939-5.

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, Matsumura N.Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664-6. doi: 10.1016/j.ygyno.2019.11.013. [Epub ahead of print]

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.Lung Cancer. 2019 Nov 3;139:28-34. doi: 10.1016/j.lungcan.2019.10.028. [Epub ahead of print]

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.
Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K.Oncogenesis. 2019 Sep 30;8(10):54. doi: 10.1038/s41389-019-0164-9.

[Current Status and Future Direction of Cancer Genomic Medicine].
Nishio K, Sakai K.Gan To Kagaku Ryoho. 2019 Sep;46(9):1357-1360. Japanese.

Clinical and immune profiling for cancer of unknown primary site.
Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K.J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.J Cancer. 2020 Jan 1;126(1):219-227. doi: 10.1002/cncr.32481. Epub 2019 Sep 10.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, Klein S, Kim Y, MacLeod AR, Sugimoto K, Yoshikawa K, Nishio K, Uemura H.J JCI Insight. 2019 Sep 5;4(17). pii: 122688. doi: 10.1172/jci.insight.122688.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.
Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K.J Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9.

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M.J Cancer Sci. 2019 Oct;110(10):3350-3357. doi: 10.1111/cas.14153. Epub 2019 Aug 19.

Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed.
Takeda M, Sakai K, Nishio K, Nakagawa K.Onco Targets Ther. 2019 Jul 8;12:5355-5358.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
Iwahashi N, Sakai K, Noguchi T,Yahata T, Matsukawa H,Toujima S, Nishio K, Ino K.Sci Rep. 2019 Jul 18;9(1):10426.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.
Watanabe S, Otani T, Iwasa T,Takahama T, Takeda M, Sakai K,Nishio K, Ito A, Nakagawa K.Clin Breast Cancer. 2019 Jun 20. pii: S1526-8209(19)30233-2.

New Era for Next-Generation Sequencing in Japan.
Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K. Cancers (Basel). 2019 May 28;11(6). pii: E742.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T,Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F,Kumagai T. Lung Cancer. 2019 Jun;132:59-64.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K, Sakai K, Takeshita M,Harada D, Azuma K, Ota K,Akamatsu H, Goto K, Horiike A,Kurata T, Nakagaki N, Nosaki K,Iwama E, Nakanishi Y, Nishio K,Okamoto I. Oncologist. 2019 Aug;24(8):1022-1026.

2018年度

Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.
Sakai K, Ohira T,Matsubayashi J, Yoneshige A,Ito A, Mitsudomi T, Nagao T,Iwamatsu E, Katayama J,Ikeda N, Nishio K. Cancer Science. 2019 Jun;110(6):2044-2049.

Myelodysplastic/myeloproliferativ e neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
Aoyama Y, Sakai K, Kodaka T, Tsunemine H, Nishio K, Itoh T, Inoue D, Takahashi T. J Clin Exp Hematop. 2019 Mar 27;59(1):29-33.

RASGRP2 suppresses apoptosis via inhibition of ROS production in vascular Endothelial Cells.
Sato T, Takino JI, Nagamine K, Nishio K, Hori T. ScientificWorldJournal. 2019 Jan 1;2019:4639165.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K. J Clin Oncol. 2019 Mar 1;37(7):570-579.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation
Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K. Lung Cancer. 2019 Jan;127:59-65.

HOXA10 expression profiling in prostate cancer.
Hatanaka Y, de Velasco MA, Oki T, Shimizu N, Nozawa M, Yoshimura K, Yoshikawa K, Nishio K, Uemura H. Prostate. 2019 Apr;79(5):554-563.

aCGH analysis of predictive biomarkers for response to bevacizumab plus oxaliplatinor irinotecan-based chemotherapy in patients with metastatic colorectal cancer.
Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Oncologist. 2019 Mar;24(3):327-337.

A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.
Iwahashi N, Sakai K, Noguchi T, Yahata T, Toujima S, Nishio K, Ino K. Oncol Lett. 2018 Nov;16(5):6431-6436.

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signalregulated kinase in non-small cell lung cancer.
Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K. Cancer Sci.110(1):52-60

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multiinstitutional research study.
Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, BMC cancer.18(1):828

Exploration of resistance mechanisms for epidermal growth factor receptortyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Cancer Sci. 2018 Dec;109(12):3921-3933.

Serpina3n, dominantly expressed in female osteoblasts, suppresses the phenotypes of differentiated osteoblasts in mice.
Ishida M, Kawao N, Okada K, Tatsumi K, Sakai K, Nishio K, Kaji H. Endocrinology. 2018 Nov 1;159(11):3775-3790

An HER3-targeting antibodydrug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K. Oncogene. 2019 Feb;38(9):1398-1409.

Clinical Practice Guidance for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0).
Sunami K, et al. Cancer Sci. 2018 Sep;109(9):2980-2985.

Heterogeneity of EGFR-mutant clones and PD-L1 highlyexpressing clones affects treatment efficacy of EGFRTKI and PD-1 inhibitor.
Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F. Ann Oncol. 2018 Oct 1;29(10):2145-2147.

A case of ALK-rearranged nonsmall cell lung cancer that responded to ceritinib after development of resistance to alectinib.
Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K. Oncotarget.9(33):23315-23319.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K. Oncotarget.9(30):21132-21140.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2- positive metastatic breast cancer.
Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K. Breast Cancer. 2018 Sep;25(5):605-613.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Breast. 2018 Aug;40:67-75.

Genital mucosal melanoma with somatic SF3B1 R625C mutation.
Oiso N, Sakai K, Yanagihara S, Nishio K, Kawada A. Eur J Dermatol. 2018 Jun 1;28(3):414-415.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K. Clinical Cancer Research.2018 Jun 1;24(11):2653-2664.